Goldman Sachs Group Inc Rapt Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 342,190 shares of RAPT stock, worth $349,033. This represents 0.0% of its overall portfolio holdings.

Number of Shares
342,190
Previous 342,190 -0.0%
Holding current value
$349,033
Previous $417,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$1.05 - $1.72 $151,995 - $248,983
-144,758 Reduced 29.73%
342,190 $417,000
Q4 2024

Feb 11, 2025
BUY
$0.81 - $3.1 $72,247 - $276,504
89,195 Added 22.42%
486,948 $769,000
Q3 2024

Nov 14, 2024
BUY
$1.76 - $3.75 $42,178 - $89,868
23,965 Added 6.41%
397,753 $799,000
Q2 2024

Aug 13, 2024
BUY
$2.89 - $9.38 $542,062 - $1.76 Million
187,565 Added 100.72%
373,788 $1.14 Million
Q1 2024

May 15, 2024
SELL
$6.87 - $26.45 $69,084 - $265,981
-10,056 Reduced 5.12%
186,223 $1.67 Million
Q4 2023

Feb 13, 2024
BUY
$11.28 - $25.46 $206,525 - $466,147
18,309 Added 10.29%
196,279 $4.88 Million
Q3 2023

May 14, 2024
SELL
$16.34 - $24.66 $299,169 - $451,499
-18,309 Reduced 9.33%
177,970 $2.96 Million
Q3 2023

Nov 14, 2023
SELL
$16.34 - $24.66 $158,645 - $239,423
-9,709 Reduced 5.17%
177,970 $2.96 Million
Q2 2023

May 14, 2024
BUY
$16.06 - $21.61 $218,672 - $294,241
13,616 Added 7.82%
187,679 $3.51 Million
Q2 2023

Aug 14, 2023
BUY
$16.06 - $21.61 $218,672 - $294,241
13,616 Added 7.82%
187,679 $3.51 Million
Q1 2023

May 14, 2024
SELL
$17.19 - $30.8 $409,414 - $733,563
-23,817 Reduced 12.04%
174,063 $3.19 Million
Q1 2023

May 11, 2023
SELL
$17.19 - $30.8 $409,414 - $733,563
-23,817 Reduced 12.04%
174,063 $3.19 Million
Q4 2022

May 14, 2024
BUY
$16.28 - $24.6 $521,546 - $788,085
32,036 Added 19.32%
197,880 $3.92 Million
Q4 2022

Feb 13, 2023
BUY
$16.28 - $24.6 $521,546 - $788,085
32,036 Added 19.32%
197,880 $3.92 Million
Q3 2022

May 14, 2024
BUY
$17.96 - $30.46 $2.48 Million - $4.2 Million
137,883 Added 493.13%
165,844 $3.99 Million
Q3 2022

Nov 10, 2022
BUY
$17.96 - $30.46 $2.48 Million - $4.2 Million
137,883 Added 493.13%
165,844 $3.99 Million
Q2 2022

May 14, 2024
SELL
$10.26 - $23.59 $1.73 Million - $3.97 Million
-168,318 Reduced 85.75%
27,961 $511,000
Q2 2022

Aug 15, 2022
SELL
$10.26 - $23.59 $232,296 - $534,101
-22,641 Reduced 44.74%
27,961 $511,000
Q1 2022

May 16, 2022
BUY
$17.02 - $40.22 $244,083 - $576,795
14,341 Added 39.55%
50,602 $1.11 Million
Q4 2021

Feb 14, 2022
BUY
$29.5 - $39.5 $138,591 - $185,571
4,698 Added 14.88%
36,261 $1.33 Million
Q3 2021

Nov 10, 2021
BUY
$29.86 - $39.47 $942,471 - $1.25 Million
31,563 New
31,563 $980,000

Others Institutions Holding RAPT

# of Institutions
100
Shares Held
134M
Call Options Held
41.3K
Put Options Held
100
View Full List

About RAPT Therapeutics, Inc.

RAPT Quotes by TradingView
  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $30.2M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email